Compare Lockheed Martin Corporation (LMT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Organon & Co. Common Stock — how do they compare? Lockheed Martin Corporation trades at $522.58 (market cap $116.32B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lockheed Martin Corporation is far larger — about 32.1× Organon & Co. Common Stock's market cap, and Lockheed Martin Corporation pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Organon & Co. Common Stock for 0 Days on average.
| LMT | OGN | |
|---|---|---|
Market Cap | $116.32B | $3.62B |
Volume | 860,316 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $676.70 | $13.81 |
52-Week Low | $439.19 | $5.70 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $133.07B | $11.04B |
Dividend Yield | 2.86% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $522.23, up 2.02% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $75.05 billion in 2025, with net income of $5.02 billion, though recent quarters show mixed earnings results. Analysts maintain a strong buy consensus with a $625.64 price target. Recent news highlights ongoing dividend increases, AI integration efforts, and new defense contracts, supporting long-term growth prospects amid stable cash flows.
The outlook for LMT is positive, driven by robust defense spending and strategic innovations, but risks include reliance on government contracts and fixed-price contract volatility. The stock offers value with a P/E of 18.58 and a dividend yield supported by 23 years of increases, though technical indicators suggest near-term caution.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
